Literature DB >> 29107058

Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.

Min-Chul Kim1, Yu-Na Lee1, Yu-Jin Kim2, Hyo-Jick Choi3, Ki-Hye Kim2, Youn-Jeong Lee4, Sang-Moo Kang5.   

Abstract

Current influenza vaccines provide hemagglutinin (HA) strain-specific protection. To improve cross protection, we engineered replication-competent influenza A virus to express tandem repeats of heterologous M2 extracellular (M2e) domains in a chimeric HA. M2e epitopes conjugated to HA glycoproteins (M2e4x-HA) were found to be expressed on the surfaces of a replicable influenza virus as examined by electron microscopy. The recombinant influenza virus containing M2e4x-HA was moderately attenuated but superior to the parental virus in inducing M2e specific antibodies without compromising HA immunogenicity. Recombinant influenza virus immune mice showed better cross protection than parental virus immune mice. Immune sera from the mice with inoculation of live recombinant influenza virus expressing M2e4x-HA were effective in conferring protection against H1, H3, and H5 subtype influenza viruses. This study indicates that recombinant influenza virus expressing conserved protective epitopes in an HA chimeric form can provide a new approach for improving the efficacy of influenza vaccines.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chimeric M2e4x-HA protein; Recombinant influenza virus; Universal influenza vaccine; Viral vector

Mesh:

Substances:

Year:  2017        PMID: 29107058      PMCID: PMC5699712          DOI: 10.1016/j.antiviral.2017.10.018

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  49 in total

1.  Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice.

Authors:  H H Nguyen; F W van Ginkel; H L Vu; M J Novak; J R McGhee; J Mestecky
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 2.  Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.

Authors:  Michael T Osterholm; Nicholas S Kelley; Alfred Sommer; Edward A Belongia
Journal:  Lancet Infect Dis       Date:  2011-10-25       Impact factor: 25.071

3.  Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

Authors:  Christine B Turley; Richard E Rupp; Casey Johnson; David N Taylor; Julie Wolfson; Lynda Tussey; Uma Kavita; Lawrence Stanberry; Alan Shaw
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

4.  Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.

Authors:  Yu-Na Lee; Young-Tae Lee; Min-Chul Kim; Hye Suk Hwang; Jong Seok Lee; Ki-Hye Kim; Sang-Moo Kang
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

5.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

Review 6.  Designing vaccines for pandemic influenza.

Authors:  Taisuke Horimoto; Yoshihiro Kawaoka
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

7.  Heterosubtypic immunity to influenza A virus infection requires a properly diversified antibody repertoire.

Authors:  Huan H Nguyen; Michael Zemlin; Ivaylo I Ivanov; Judit Andrasi; Cosima Zemlin; Huong L Vu; Robert Schelonka; Harry W Schroeder; Jiri Mestecky
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

8.  Human infection with a novel avian-origin influenza A (H7N9) virus.

Authors:  Rongbao Gao; Bin Cao; Yunwen Hu; Zijian Feng; Dayan Wang; Wanfu Hu; Jian Chen; Zhijun Jie; Haibo Qiu; Ke Xu; Xuewei Xu; Hongzhou Lu; Wenfei Zhu; Zhancheng Gao; Nijuan Xiang; Yinzhong Shen; Zebao He; Yong Gu; Zhiyong Zhang; Yi Yang; Xiang Zhao; Lei Zhou; Xiaodan Li; Shumei Zou; Ye Zhang; Xiyan Li; Lei Yang; Junfeng Guo; Jie Dong; Qun Li; Libo Dong; Yun Zhu; Tian Bai; Shiwen Wang; Pei Hao; Weizhong Yang; Yanping Zhang; Jun Han; Hongjie Yu; Dexin Li; George F Gao; Guizhen Wu; Yu Wang; Zhenghong Yuan; Yuelong Shu
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

Review 9.  A "universal" human influenza A vaccine.

Authors:  W Fiers; M De Filette; A Birkett; S Neirynck; W Min Jou
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

10.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

Authors:  Jiang Fan; Xiaoping Liang; Melanie S Horton; Helen C Perry; Michael P Citron; Gwen J Heidecker; Tong-Ming Fu; Joseph Joyce; Craig T Przysiecki; Paul M Keller; Victor M Garsky; Roxana Ionescu; Yvette Rippeon; Li Shi; Michael A Chastain; Jon H Condra; Mary-Ellen Davies; Jason Liao; Emilio A Emini; John W Shiver
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

View more
  6 in total

1.  Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Authors:  Ki-Hye Kim; Yu-Jin Jung; Youri Lee; Bo Ryoung Park; Judy Oh; Yu-Na Lee; Min-Chul Kim; Subbiah Jeeva; Sang-Moo Kang
Journal:  Virology       Date:  2020-08-22       Impact factor: 3.616

2.  Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.

Authors:  Bo Ryoung Park; Jeeva Subbiah; Ki-Hye Kim; Young-Man Kwon; Judy Oh; Min-Chul Kim; Chong-Hyun Shin; Baik Lin Seong; Sang-Moo Kang
Journal:  Virology       Date:  2021-12-10       Impact factor: 3.616

Review 3.  Universal influenza vaccines: from viruses to nanoparticles.

Authors:  Ye Wang; Lei Deng; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Expert Rev Vaccines       Date:  2018-11-02       Impact factor: 5.217

4.  Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin.

Authors:  Bo Ryoung Park; Ki-Hye Kim; Tatiana Kotomina; Min-Chul Kim; Young-Man Kwon; Subbiah Jeeva; Yu-Jin Jung; Noopur Bhatnagar; Irina Isakova-Sivak; Daria Mezhenskaya; Larisa Rudenko; Bao-Zhong Wang; Sang-Moo Kang
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

5.  Antiviral Activity of Fermented Ginseng Extracts against a Broad Range of Influenza Viruses.

Authors:  Ye Wang; Yu-Jin Jung; Ki-Hye Kim; Youngman Kwon; Yu-Jin Kim; Zhan Zhang; Heun-Soo Kang; Bao-Zhong Wang; Fu-Shi Quan; Sang-Moo Kang
Journal:  Viruses       Date:  2018-09-01       Impact factor: 5.048

6.  Generation and Characterization of Universal Live-Attenuated Influenza Vaccine Candidates Containing Multiple M2e Epitopes.

Authors:  Tatiana Kotomina; Irina Isakova-Sivak; Ki-Hye Kim; Bo Ryoung Park; Yu-Jin Jung; Youri Lee; Daria Mezhenskaya; Victoria Matyushenko; Sang-Moo Kang; Larisa Rudenko
Journal:  Vaccines (Basel)       Date:  2020-11-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.